These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36998454)

  • 1. Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer.
    Wang T; Shao Q; Xiao C; Liu L
    Front Oncol; 2023; 13():1124730. PubMed ID: 36998454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
    He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
    J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 blockade combined with chemotherapy and bevacizumab in DNA mismatch repair-proficient/microsatellite stable colorectal liver metastases.
    Men Q; Duan Y; Pei F; Yao Q; He W; Zhao Y; Shi L; Liu G; Huang J
    J Gastrointest Oncol; 2024 Aug; 15(4):1534-1544. PubMed ID: 39279968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report.
    Liu Y; Du J; Zhang P; Meng W; Xiao H
    Front Oncol; 2023; 13():1051786. PubMed ID: 36969074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study.
    Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY
    Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report.
    Yang J; Xing P; Kong Y; Xu M; Zhang L
    Front Oncol; 2023; 13():1078915. PubMed ID: 37188188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer.
    Ding Y; Weng S; Zhu N; Mi M; Xu Z; Zhong L; Yuan Y
    Heliyon; 2023 Nov; 9(11):e22092. PubMed ID: 38058653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report.
    Lin S; Chen W; Chen Z; Liang J; Zhong L; Jiang M
    Ann Transl Med; 2022 Mar; 10(6):380. PubMed ID: 35433988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer.
    Li Q; Cheng X; Zhou C; Tang Y; Li F; Zhang B; Huang T; Wang J; Tu S
    Front Oncol; 2022; 12():841977. PubMed ID: 35371995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study.
    Zhang W; Zhang Z; Lou S; Li D; Ma Z; Xue L
    Front Oncol; 2022; 12():929342. PubMed ID: 36119532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study.
    Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X
    Front Oncol; 2020; 10():594125. PubMed ID: 33282742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer.
    Sun L; Huang S; Li D; Mao Y; Wang Y; Wu J
    Front Oncol; 2021; 11():754881. PubMed ID: 34692541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case Report.
    He Y; Wang L; Li X; Zhang T; Song T; Zhang J; Yu Y; Chen S; Song H
    Front Oncol; 2021; 11():596342. PubMed ID: 34113555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.
    Gou M; Qian N; Zhang Y; Yan H; Si H; Wang Z; Dai G
    Front Oncol; 2022; 12():851756. PubMed ID: 35875064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
    Jiang FE; Zhang HJ; Yu CY; Liu AN
    Neoplasma; 2021 Jul; 68(4):861-866. PubMed ID: 33998237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
    Front Oncol; 2022; 12():917353. PubMed ID: 36226061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.